Clinical efficacy of bevacizumab for the treatment of serious peritumorous brain edema
10.3969/j.issn.1000-8179.2016.23.859
- VernacularTitle:贝伐珠单抗治疗难治性瘤周脑水肿的近期疗效观察
- Author:
Jin SU
;
Ying QIAN
;
Kezhi SHI
;
Yang LIU
;
Fang YI
;
Xinhua XU
- Keywords:
bevacizumab;
malignant brain tumor;
peritumorous brain edema;
edema index
- From:
Chinese Journal of Clinical Oncology
2016;43(23):1045-1048
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy of bevacizumab on the treatment of serious peritumorous brain edema. Methods:A total of 16 patients with malignant brain tumors and serious peritumorous brain edema, (13 cases of lung cancer, 2 cases of breast can-cer, and 1 case of recurrent glioblastoma) were analyzed. Treatment with glucocorticoids, osmotic dehydration, and other convention-al approaches were not effective for these patients. Bevacizumab was administered at a dose of 5 mg/kg at least once every three or four weeks. The Karnofsky performance score (KPS) and the changes in cerebral edema symptoms, such as cerebral edema volume, tu-mor volume, edema index (EI), and changes in magnetic resonance imaging (MRI) were compared before and after treatment. The t-test and least-significant difference method were used to compare treatment groups. Results:All bevacizumab-treated patients had re-duced symptoms. The KPS after treatment was significantly higher than that before treatment (P<0.001). The cerebral edema vol-umes, tumor volumes, and EI of 16 patients were significantly decreased (P<0.05). Bevacizumab caused mild clinical side effects. Con-clusion:Preliminary results showed that treatment of serious peritumorous brain edema with bevacizumab was safe and effective.
